Palisade Bio (PALI) said Thursday it has received clearance from Health Canada to start a phase 1 trial that will evaluate PALI-2108 for the treatment of ulcerative colitis.
Preparations for the trial are ongoing and Palisade is on track to begin enrollment before the end of the year, the company said.
Price: 3.31, Change: -0.01, Percent Change: -0.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments